Eledon Advances Tegoprubart In Islet Cell And Kidney Transplant Programs

Eledon Pharmaceuticals said it submitted an IND to the FDA to support a registrational study using Tegoprubart in islet cell transplantation for patients with type diabetes. The update signals regulatory and clinical program progress, which is modestly positive for the company’s development trajectory, though the article provides no efficacy or financial outcomes.